Compare Church & Dwight Co., Inc. (CHD) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Crispr Therapeutics AG — how do they compare? Church & Dwight Co., Inc. trades at $103.35 (market cap $24.38B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.23B). The key difference: Church & Dwight Co., Inc. is far larger — about 4.7× Crispr Therapeutics AG's market cap, and Church & Dwight Co., Inc. pays a 1.2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CHD | CRSP | |
|---|---|---|
Market Cap | $24.38B | $5.23B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $76.78 |
52-Week Low | $81.60 | $44.34 |
Enterprise Value | $26.38B | $3.65B |
Dividend Yield | 1.2% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
